Immunocore Holdings plc (NASDAQ:IMCR) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Immunocore Holdings plc (NASDAQ:IMCR) have received an average recommendation of “Moderate Buy” from the eleven brokerages that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and seven have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $58.89.

A number of analysts have recently commented on the company. Oppenheimer boosted their price target on Immunocore from $85.00 to $86.00 and gave the stock an “outperform” rating in a research report on Thursday, May 8th. Mizuho lowered their price objective on Immunocore from $38.00 to $33.00 and set a “neutral” rating on the stock in a research report on Monday, April 7th. Wall Street Zen cut Immunocore from a “buy” rating to a “hold” rating in a research report on Friday. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a research report on Monday, June 2nd. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $71.00 price objective on shares of Immunocore in a research report on Thursday, April 10th.

Insider Buying and Selling at Immunocore

In related news, Director Bros. Advisors Lp Baker acquired 807,338 shares of Immunocore stock in a transaction dated Monday, March 17th. The stock was purchased at an average cost of $29.72 per share, for a total transaction of $23,994,085.36. Following the purchase, the director now directly owns 2,144,060 shares of the company’s stock, valued at approximately $63,721,463.20. This trade represents a 60.40% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 10.40% of the company’s stock.

Institutional Investors Weigh In On Immunocore

Hedge funds and other institutional investors have recently modified their holdings of the stock. Assetmark Inc. increased its stake in Immunocore by 5.3% in the 4th quarter. Assetmark Inc. now owns 32,171 shares of the company’s stock worth $949,000 after buying an additional 1,616 shares in the last quarter. Primecap Management Co. CA increased its stake in Immunocore by 8.0% in the 4th quarter. Primecap Management Co. CA now owns 2,668,550 shares of the company’s stock worth $78,722,000 after buying an additional 196,530 shares in the last quarter. BIT Capital GmbH increased its stake in Immunocore by 182.7% in the 4th quarter. BIT Capital GmbH now owns 67,840 shares of the company’s stock worth $2,001,000 after buying an additional 43,840 shares in the last quarter. NEOS Investment Management LLC increased its stake in Immunocore by 10.9% in the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company’s stock worth $330,000 after buying an additional 1,102 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in Immunocore by 1.2% in the 4th quarter. Geode Capital Management LLC now owns 35,492 shares of the company’s stock worth $1,047,000 after buying an additional 420 shares in the last quarter. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

Immunocore Stock Performance

Shares of IMCR opened at $37.25 on Wednesday. The company has a quick ratio of 3.76, a current ratio of 3.78 and a debt-to-equity ratio of 1.03. The business’s 50 day moving average price is $30.23 and its 200-day moving average price is $30.17. Immunocore has a 52 week low of $23.15 and a 52 week high of $42.09. The stock has a market cap of $1.87 billion, a P/E ratio of -39.21 and a beta of 0.83.

Immunocore (NASDAQ:IMCR) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.10 EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.45. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The firm had revenue of $125.13 million for the quarter, compared to analysts’ expectations of $108.82 million. During the same period in the previous year, the firm posted ($0.49) EPS. The business’s revenue for the quarter was up 33.6% compared to the same quarter last year. Equities research analysts anticipate that Immunocore will post -0.94 earnings per share for the current fiscal year.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.